Clinical trials: Hepatocellular
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04442581
- Testing
- Cabozantinib S-malate, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Unresectable Hepatocellular Carcinoma (HCC)
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05630937
- Testing
- NMS-01940153E
- Where
- 9 sites in United States, Italy and 1 more
- Volunteers
- 31 people
- Sponsor
- Nerviano Medical Sciences
Hepatocellular Carcinoma (HCC)
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma…
- Trial name
- NCT03071094
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Nivolumab
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Transgene
Hepatocellular Carcinoma
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo…
- Trial name
- NCT05359861
- Testing
- Casdozokitug, Atezolizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Coherus Oncology, Inc.
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Localized Hepatocellular Carcinoma
STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
- Trial name
- NCT03113955
- Testing
- Tandem Microsphere loaded with Epirubicin
- Where
- 10 sites in China
- Volunteers
- 109 people
- Sponsor
- Varian Medical Systems
Hepatocellular Carcinoma
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus…
- Trial name
- CheckMate040 (NCT01658878)
- Testing
- Nivolumab, Sorafenib, Ipilimumab
- Where
- 60 sites in United States, Canada and 11 more
- Volunteers
- 657 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, Liver Cirrhoses
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Hepatocellular Carcinoma (HCC) is a major health concern in the United States, particularly among people with liver cirrhosis. Out of every 100 patients with liver cancer, only 18 will survive 5 years or more.
- Trial name
- NCT03219372
- Testing
- Pravastatin Pill
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cedars-Sinai Medical Center
Carcinoma, Hepatocellular
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT03418922
- Testing
- Lenvatinib, Nivolumab
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Eisai Co., Ltd.
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
This phase II trial studies the best dose and side effects of sorafenib tosylate and nivolumab in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to nearby tissues or lymph nodes…
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03439891
- Testing
- Nivolumab, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Robin Kate Kelley
Hepatocellular Carinoma
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in…
- Trial name
- FLASH (NCT01636284)
- Testing
- JX-594 recombinant vaccina GM-CSF
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- Jennerex Biotherapeutics
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
- Trial name
- NCT01754987
- Testing
- Ascorbic Acid + Sorafenib, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting.
- Trial name
- NCT04740307
- Testing
- Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
- Where
- 40 sites in United States, China and 7 more
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obese
The Effect of Protein-enriched Diet on Body Composition and Appetite
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Overweight, Obese, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
- Trial name
- ProteinRich (NCT01634048)
- Testing
- High Protein, low calorie meal replacement
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatocellular Carcinoma
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic…
- Trial name
- NCT01203787
- Testing
- Sorafenib Standard Dosing Regimen, Sorafenib Ramp-Up Regimen
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Florida
Hepatocellular Carcinoma
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
- Trial name
- NCT00906373
- Testing
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of…
- Trial name
- NCT04194775
- Testing
- Nofazinlimab (CS1003)+Lenvatinib
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 534 people
- Sponsor
- CStone Pharmaceuticals
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany